- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 105 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- September 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- November 2023
- 71 Pages
France
From €3327EUR$3,500USD£2,795GBP
- Report
- February 2024
- 185 Pages
North America
From €3280EUR$3,450USD£2,755GBP
- Report
- March 2023
- 185 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- October 2023
- 146 Pages
Africa, Middle East
From €3280EUR$3,450USD£2,755GBP
- Report
- October 2023
- 145 Pages
From €3280EUR$3,450USD£2,755GBP
- Report
- July 2023
- 198 Pages
Europe
From €3280EUR$3,450USD£2,755GBP
- Report
- June 2023
- 184 Pages
Asia Pacific
From €3280EUR$3,450USD£2,755GBP
- Report
- July 2023
- 140 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Book
- December 2021
- 304 Pages
Radiopharmaceutical Theranostics is a field of Nuclear Medicine and Radiopharmacology that focuses on the development of radiopharmaceuticals for the diagnosis and treatment of diseases. Radiopharmaceuticals are drugs that contain radioactive isotopes and are used to diagnose and treat diseases such as cancer, heart disease, and neurological disorders. Theranostics is a combination of the words “therapy” and “diagnostics” and refers to the use of radiopharmaceuticals for both diagnosis and treatment. Radiopharmaceutical Theranostics is a rapidly growing field, with new developments in imaging technology and radiopharmaceuticals allowing for more accurate diagnosis and treatment of diseases.
Some companies in the Radiopharmaceutical Theranostics market include GE Healthcare, Siemens Healthineers, Mallinckrodt Pharmaceuticals, and Bracco Diagnostics. Show Less Read more